Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SMS 2: Impact of Cancer Therapy on the Somatic Mutational Landscape of Normal Tissues

NCT06832150 is registered in ClinicalTrials.gov with The Wellcome Sanger Institute as lead sponsor.

NCT NCT06832150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06832150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SMS 2: Impact of Cancer Therapy on the Somatic Mutational Landscape of Normal Tissues
Lead sponsor
The Wellcome Sanger Institute
Phase
Observational
Overall status
Enrolling by invitation
Start date
November 26, 2024
Completion date
May 13, 2029
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, somatic mutation